InVivo Therapeutics has suspended enrollment in a trial evaluating its Neuro-Spinal Scaffold for treatment of complete thoracic AIS A spinal-cord injury, after the study recorded three patient deaths. InVivo said the deaths were not related to the implantation procedure or the device, but company leaders will work with the FDA to determine whether enrollment criteria should be revised.
InVivo suspends enrollment in Neuro-Spinal Scaffold trial
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.